Otsuka and Ionis Pharmaceuticals advanced their amyotrophic lateral sclerosis program after a Phase 3 study hit its primary endpoint. The result positions the partners to seek expedited regulatory pathways, with discussions now expected as the clinical evidence packet moves toward submission. The therapy, ulefnersen, is an RNA-based drug targeting a rare ALS subtype. The next steps are likely to focus on durability of effect and safety monitoring, particularly given the high bar for benefit in ALS. For the ALS market, the update matters because it changes the near-term probability of a new disease-modifying option and may influence how clinicians sequence emerging RNA therapeutics.